Nasdaq ikna.

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) announced an agreement to acquire an approximately 48,000-square-foot R&D facility in Frederick, Maryland to support its expanding infectious ...Ikena Oncology, Inc. (IKNA) NasdaqGM - NasdaqGM Real Time Price. Currency in USD. Follow. 2W 10W 9M. 1.6700 +0.0900 (+5.70%) As of 10:38AM EST. Market open. 1d. The latest price target for . Ikena Oncology (NASDAQ: IKNA) was reported by HC Wainwright & Co. on November 9, 2023.The analyst firm set a price target for $11.00 expecting IKNA to rise to within ...BOSTON, May 15, 2023 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”, ... The Invesco QQQ Trust offers a way to play tech strength by matching the Nasdaq 100 index.Jun 22, 2022 · BOSTON, June 22, 2022 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced ...

Mar 7, 2022 · BOSTON, March 07, 2022 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA), a targeted oncology company navigating new territory in patient-directed cancer treatment, today announced that it ... 17 déc. 2021 ... ... (NASDAQ: ADGI), Icosavax (NASDAQ: ICVX), Imago BioSciences (NASDAQ: IMGO), Ikena Oncology (NASDAQ: IKNA), Nuvation Bio (NYSE: NUVB), Sana ...

Ikena Oncology, Inc. (NASDAQ:IKNA) is a Boston, Massachusetts-based company with a strong pipeline. Ikena Oncology, Inc. (NASDAQ:IKNA) went public in 2021. In November last year, Ikena Oncology, Inc.Ikena™ is redefining the targeted oncology landscape and envisions a world in which every cancer patient has a cure. We develop therapies that target the underlying mechanisms …

Acquisition Corp. (NASDAQ: INKA) announced it has entered into a business combination agreement with Near Intelligence Holdings, Inc. in a de-SPAC transaction On November 14, 2022. TLG Acquisition One Corp. (NYSE: TLGA) announced it has entered into a business combination agreement with ElectrIQ Power, Inc. in a de-SPAC transaction FAIRNESS …BOSTON, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company navigating new territory in patient-directed cancer treatment, today ...The Investor Relations website contains information about Nasdaq, Inc.'s business for stockholders, potential investors, and financial analysts.7 août 2023 ... (Nasdaq: IKNA, Ikena), a targeted oncology company forging new territory in patient-directed cancer treatment, and Pionyr Immunotherapeutics ...

IKNA has a market cap of $253mn and a cash balance of $157mn. Research and development expenses were $64.3 million for the year ended December 31, 2022 and general and administrative expenses were ...

About Nasdaq Nasdaq (Nasdaq: NDAQ) is a global technology company serving the capital markets and other industries. Our diverse offering of data, analytics, software, and services enables clients ...

Analyst Forecast According to 4 analysts, the average rating for IKNA stock is "Strong Buy." The 12-month stock price forecast is $14.25, which is an increase of …May-16-23 08:29AM · Party Time: Brokers Just Made Major Increases To Their Ikena Oncology, Inc. (NASDAQ:IKNA) Earnings Forecasts. (Simply Wall St.) -12.00% ; 09: ...BOSTON, June 22, 2022 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced ...BOSTON, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company forging new territory in patient-directed cancer treatment, today presented ...Every investor in Ikena Oncology, Inc. (NASDAQ:IKNA) should be aware of the most powerful shareholder groups. Insiders often own a large chunk of younger, smaller, companies while huge companies ...

... (NASDAQ: IKNA). Levi & Korsinsky, LLP (PRNewsfoto/Levi & Korsinsky, LLP). News provided by. Levi & Korsinsky, LLP. Oct 02, 2023, 5:45 AM ET. NEW YORK ...Find the latest Ikena Oncology Inc (IKNA) discussion and analysis from iHub's community of investors ... NASDAQ · Add Alert · Follow. 1. 1.71. 0.00 (0.00%). Quote ...Ikena Oncology (NASDAQ:IKNA) reported its Q3 earnings results on Thursday, November 9, 2023 at 07:00 AM.. Here's what investors need to know about the announcement. Earnings. Ikena Oncology beat ... Ikena Oncology, Inc. (NASDAQ:IKNA) announced its earnings results on Wednesday, November, 10th. The company reported ($0.40) EPS for the quarter, topping analysts' consensus estimates of ($0.42) by $0.02. The business earned $3.75 million during the quarter, compared to analysts' expectations of $2.92 million.Overview Stock Screener Earnings Calendar Sectors Nasdaq | IKNA U.S.: Nasdaq Ikena Oncology Inc. Watch list Set a price target alert After Hours Last Updated: Nov 9, 2023 6:00 p.m. EST...Find the latest news headlines from Ikena Oncology, Inc. Common Stock (IKNA) at Nasdaq.com.Ikena Oncology Stock Price, News & Analysis (NASDAQ:IKNA) $1.50 +0.05 (+3.45%) (As of 12/1/2023 ET) Compare Share Today's Range $1.42 $1.52 50-Day …

Mike Powell, Ph.D., joined Omega Funds in August 2021 from Sofinnova Investments, where he served as Managing General Partner since 1997. Previously, he was Group Leader at Genentech, where his ...The public float for IKNA is 25.79M and currently, short sellers hold a 4.01% ratio of that float. The average trading volume of IKNA on November 29, 2023 was 174.06K shares. IKNA) stock’s latest price update. Ikena Oncology Inc (NASDAQ: IKNA)’s stock price has dropped by -10.56 in relation to previous closing price of 1.61.

BOSTON, Oct. 07, 2021 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company navigating new territory in patient-directed cancer treatment, today ...Check the Ikena Oncology, Inc. stock price today on the NASDAQ stock exchange and access historical IKNA stock price chart. Get the latest Ikena Oncology, ...Ikena Oncology (NASDAQ:IKNA) reported its Q3 earnings results on Thursday, November 9, 2023 at 07:00 AM.. Here's what investors need to know about the announcement. Earnings. Ikena Oncology beat ... The Index is designed to track the performance of a set of securities listed on The Nasdaq Stock Market ® that are classified as either biotechnology or pharmaceutical according to the Industry ...May 15, 2023 · Financial Results for the Quarter Ended March 31, 2023. As of March 31, 2023, Ikena had $137.8 million in cash, cash equivalents and marketable securities, which does not include proceeds from the ... According to 4 analysts, the average rating for IKNA stock is "Strong Buy." The 12-month stock price forecast is $16.0, which is an increase of 288.35% from the latest price.23 mai 2023 ... Dolar, Borsa, Altın, Eurobond, Bankalar ve Nasdaq Hakkında ... İlahiyatçı Kızlar Celal Şengör'ü "Bir Yaratan" Olduğuna İkna Etmeye Çalışıyorlar.Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 15)

Find the latest news headlines from Ikena Oncology, Inc. Common Stock (IKNA) at Nasdaq.com.

Provention Bio, Inc. (NASDAQ:PRVB), said it has been notified by the FDA that it has identified deficiencies in the company's biologic license application for teplizumab for the delay or ...

BOSTON, May 15, 2023 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”, “Company”), a targeted oncology company forging new territory in patient-directed cancer treatment, announced today the pricing of an underwritten offering of 6,110,000 shares of common stock (the “Shares”) at an offering price of $6.55 per share.Ikena Oncology, Inc. (IKNA) Reports Q2 Loss, Lags Revenue Estimates. Zacks • Aug 10, 2023. Kronos Bio, Inc. (KRON) Reports Q2 Loss, Misses Revenue Estimates.Ikena Oncology Inc (NASDAQ:IKNA). Real-Time Quotes. 1.50. BATS BZX Real-Time Price. As of 11:15am ET. +0.045 / +3.09%. Today's Change. 1.02. Today|||52-Week ...Oct 18, 2022 · Company shares further detail on the differentiators of IK-930, a TEAD-paralog selective inhibitor. BOSTON, Oct. 18, 2022 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a ... BOSTON, Nov. 28, 2022 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced a next-generation mitogen-activated protein kinase (MEK)-RAF complex inhibitor, IK-595, has been nominated as the company’s first development ...BOSTON, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company forging new territory in patient-directed cancer treatment, today presented initial clinical data from its ongoing IK-175 clinical program in urothelial carcinoma at the Society for Immunotherapy of Cancer (SITC) 37 th Annual ...BOSTON, March 06, 2023 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for IK-175, the Company’s novel aryl hydrocarbon receptor (AHR ...BOSTON, Dec. 08, 2021 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company navigating new territory in patient-directed cancer treatment, today ...Nov. 07, 2023 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena,” “Company”), a targeted oncology company forging new territory in patient-directed cancer treatment, today ...PASADENA, Calif., Nov. 9, 2022 /PRNewswire/ -- Near, a global, full-stack data intelligence software-as-a-service ("SaaS") platform that stitches and enriches data on people and places ("Near", or the "Company") today announced that it will have access to up to $100 million from Blue Torch Capital, as it prepares for its next phase of growth of becoming a …

Ikena Oncology (NASDAQ:IKNA) reported its Q3 earnings results on Thursday, November 9, 2023 at 07:00 AM.. Here's what investors need to know about the announcement. Earnings. Ikena Oncology beat ... List with Nasdaq; Nasdaq Private Market; Nasdaq Fund Secondaries; Investor Relations Intelligence ; Nasdaq Direct Listings; Optimize Governance Practices. Board Portal …Why Ikena Oncology (IKNA) Might Surprise This Earnings Season finance.yahoo.com - May 10 at 11:04 AM: Equities Analysts Offer Predictions for Ikena Oncology, Inc.'s Q1 2023 Earnings (NASDAQ:IKNA) marketbeat.com - May 8 at 1:22 AM: Ikena Oncology (NASDAQ:IKNA) Receives New Coverage from Analysts at HC Wainwright marketbeat.com - May 5 at 11:17 AMInstagram:https://instagram. delta airline pilot paytop dental insurance ny1943 no mint mark pennyequitybee alternatives Ikena Oncology Inc (NASDAQ:IKNA) showed a performance of -46.11% in past 30-days. Number of shares sold short was 1.28 million shares which calculate 16.64 days to cover the short interests. Wall Street analysts have assigned a consensus price target of $8.33 to the stock, which implies a rise of 78.39% to its current value.Dec 25, 2021 · See All Market Activity. News + Insights. CLOSE top financial advisors in minnesotaeps stocks 19 oct. 2022 ... (Nasdaq: IKNA, “Ikena”), una compañía de oncología específica que forja un nuevo territorio en el tratamiento del cáncer dirigido por el ... stock pdi Selected Balance Sheet Items: September 30, 2023 December 31, 2022: Cash and cash equivalents $ 121,277 $ 59,919 Marketable securities $ 75,656Shares of Chembio Diagnostics, Inc. (NASDAQ:CEMI) got a boost, shooting 57% to $5.53 after the company announced the commercial launch of a test to differentiate between COVID-19 and the Flu.Ikena Oncology Inc (NASDAQ:IKNA) showed a performance of -46.11% in past 30-days. Number of shares sold short was 1.28 million shares which calculate 16.64 days to cover the short interests. Wall Street analysts have assigned a consensus price target of $8.33 to the stock, which implies a rise of 78.39% to its current value.